The adoptive transfer of antigen-specific CD8 + T cells is a promising approach for the treatment of chronic viral and malignant diseases. In order to improve adoptive T cell therapy (ATT) of cancer, recent strategies aim at the antibody-based blockade of immunosuppressive signaling pathways in CD8 + T cells. Alternatively, adjuvant effects of immunostimulatory cytokines might be exploited to improve therapeutic CD8 + T cell responses. For example, Interleukin-7 (IL-7) is a potent growth, activation and survival factor for CD8 + T cells that can be used to improve virus-and tumor-specific CD8 + T cell responses. Although direct IL-7 effects on CD8 + T cells were studied extensively in numerous models, the contribution of IL-7 receptor-competent (IL-7R + ) host cells remained unclear. In the current study we provide evidence that CD8 + T cell-mediated tumor rejection in response to recombinant IL-7 (rIL-7) therapy is strictly dependent on IL-7R + host cells. On the contrary, CD8 + T cell expansion is independent of host IL-7R expression. If, however, rIL-7 therapy and peptide vaccination are combined, host IL-7R signaling is crucial for CD8 + T cell expansion. Unexpectedly, maximum CD8 + T cell expansion relies mainly on IL-7R signaling in non-hematopoietic host cells, similar to the massive accumulation of dendritic cells and granulocytes. In summary, we provide evidence that IL-7R + host cells are major targets of rIL-7 that modulate therapeutic CD8 + T cell responses and the outcome of rIL-7-assisted ATT. This knowledge may have important implications for the design and optimization of clinical ATT protocols.
Introduction
The size of the peripheral T cell pool is remarkably stable throughout life. Although infections can cause a strong increase in T cell numbers, they usually return to steady-state levels after pathogen clearance. This indicates that self-regulatory mechanisms maintain T cell numbers [1] . A central factor controlling peripheral T cell homeostasis is IL-7. It acts as a growth and survival signal for T cells, which express the IL-7R and constitutively consume IL-7 [2] . Consequently, the size of the peripheral T cell pool becomes self-limiting as soon as IL-7 production and consumption reach an equilibrium [1] . Due to the lack of IL-7 consumption by T cells, IL-7 availability is increased in lymphopenic humans [3] and mice [4] . Lymphopenia-associated IL-7 overabundance contributes to the activation of naïve T cells, which undergo homeostatic or lymphopenia-induced proliferation (LIP) and convert into memory-like cells, which express high levels of CD44 and IFNγ [5] .
The adoptive transfer of antigen-specific T cells is an important therapeutic option for the treatment of viral infections and cancer and has been performed successfully in animal models as well as in the clinic [6, 7] . It is well established that the efficacy of adoptive T cell therapy (ATT) can be improved if recipient T cells are depleted by chemotherapy or irradiation prior to T cell transfer [6, 8] . This positive effect of lymphodepletion results from the increased availability of T cell growth and survival factors such as IL-7 [9, 10] .
From our own experiments we know that thymus, lymph nodes, skin and intestine are the major sources of IL-7 in the mouse [11, 12] . Nevertheless, steady-state IL-7 production is not sufficient for effective anti-tumor T cell responses under non-lymphopenic conditions. The injection of recombinant IL-7 (rIL-7) circumvents this problem and boosts anti-tumor T cell responses [13, 14] . Since IL-7 promotes T cell survival [15, 16] , activation [17, 18] , proliferation [19] and memory T cell (T M ) formation [20] its direct action on T cells is supposed to be the major cause for its potent anti-tumor effects [21] . For the effective treatment of viral infections and cancer by ATT high numbers of adoptively transferred CD8 + cells are required in vivo [7] .
Their longevity and subsequent accumulation can be improved by rIL-7 therapy suggesting that this approach can be used to improve ATT [21] . Importantly, the adjuvant effects of rIL-7 correlate with tumor growth delay rather than complete rejection [13, 22, 23] . Given that i) regulatory immune cells such as dendritic cells (DCs) and granulocytes expand in response to elevated IL-7 levels [24, 25] and ii) non-hematopoietic cells such as fibroblasts and intestinal epithelial cells express functional IL-7 receptors (IL-7R) [12, 26] , we hypothesized that IL-7R + host cells might modulate anti-tumor CD8 + T cell responses.
In the current study we asked whether and how host IL-7R signaling affects ATT efficacy. For this purpose we established an ATT model, which enabled us to discriminate between direct and indirect effects of rIL-7 therapy on tumor-specific CD8 + T cells. Our data demonstrate, that LIP of CD8 + T cells and subsequent T M differentiation are promoted by rIL-7 in a host IL-7R-independent manner. However, tumor rejection strictly requires host IL-7R expression. Furthermore, we show that IL-7R + non-hematopoietic host cells are crucial for maximum CD8 + T cell expansion and T M differentiation if rIL-7 therapy is combined with peptide vaccination. Importantly, despite efficient CD8 + T cells expansion, peptide vaccination deteriorates rIL-7-dependent ATT efficacy. In summary, we provide evidence that host IL-7R signaling modulates multiple aspects of CD8 + T cells activation and T M differentiation and can promote tumor rejection in a context-dependent fashion. -restricted peptide OVA 257-264 (SIINFEKL)), IL-7GCDL [11] and ChRluc mice [27] were bred in our animal facilities. All mice were housed under specific pathogen-free conditions. Animal experiments were performed according to institutional guidelines and were approved by the Landesamt für Gesundheit und Soziales Berlin (Permit Number: G0170/08) and Landesverwaltungsamt Sachsen-Anhalt (Permit Number: 2-1155 Uni MD).
Materials and Methods

Mice
Generation of bone marrow (BM) chimeras and bioluminescence detection
BM recipients were anesthetized (Ketamin/Rompun i.p.), irradiated lethally and injected with BM cells i.v. 6-18 hours later. Donor BM was isolated from femur and tibia. BM from one donor was used to reconstitute 3 recipients. BM chimeras received antibiotics via the drinking water for 3-4 weeks and were used for experiments earliest 6 weeks after BM injection. To visualize luciferase activity in live animals, bioluminescence intensities (BLI) were measured using the IVIS Imaging system (Xenogen) as described before [11, 27] .
Adoptive T cell transfer, peptide vaccination and IL-7 treatment
Naïve CD8 + T cells were purified from spleen and lymph nodes of the respective donor mice using CD8α-specific microbeads and AutoMACS (Miltenyi Biotec). Tumor cell challenge 
Flow cytometry
The following antibodies were used: anti-CD8α (53-6.7; eBioscience/Biolegend/BD), -CD90.1 (OX-7; Biolegend/BD), -CD62L (MEL-14; Biolegend/BD), -CD44 (IM7; eBioscience/Biolegend/BD), -KLRG-1 (2F1; eBioscience), PD-1 (J43; eBioscience), -Ki67 (SolA15; eBioscience), CD127 (A7R34; BD/Biolegend), CD132 (TUGm2; BD), -Bcl-2 (10C4; Biolegend), -IFN-γ (XMG1.2; Biolegend/eBioscience), -TNF-α (MP6-XT22; BD), -CD11c (N418; BD/Biolegend), -CD11b (MI70; BD/Biologend), Gr-1 (RB6-8-C5; Biolegend). Stimulation of CD8 + OT-I T cells with SIINFEKL and subsequent intracellular cytokine staining was performed as described recently [28] . Samples were measured on FACSCalibur, FACSCanto or LSRII flow cytometers and analyzed by FlowJo software (FlowJo, LLC).
Statistical analysis
Statistical analysis and graphical representations were done using Prism5 software (GraphPad Software). Statistical significance was determined using a non-parametric two-tailed Fig 1A) . Nevertheless, only 1 mouse out of 11 remained long-term tumor-free. In order to investigate whether IL-7 therapy promotes tumor rejection, groups of OT-Ireconstituted Rag -/-mice received rIL-7 every 3-4 days for 18 days starting one day prior to adoptive T cell transfer. To improve its function, rIL-7 was complexed with IL-7-specific antibodies (αIL-7) prior to injection as described before [29] . 7/12 Rag -/-mice receiving OT-I T cells plus IL-7 therapy completely rejected EG7 lymphoma cells demonstrating that IL-7 therapy strongly enhances OT-I-dependent tumor rejection in our experimental system ( Fig 1A) . Importantly, rIL-7 treatment did not affect primary EG7 growth in either host (data not shown). Several studies provided evidence that rIL-7 promotes activation, survival, function of CD8 + T cells [15] [16] [17] [18] [19] 30] and memory T cell (T M ) formation [20] . So far, however, these effects were considered to result from direct effects of rIL-7 on CD8 + T cells. Besides CD8 + T cells, however, numerous hematopoietic and non-hematopoietic cells express the IL-7 receptor (IL-7R) [31] . Hence, it remained unclear whether the success of IL-7-assisted adoptive T cell transfers relies on IL-7R signaling in CD8 + T cells and/or host cells. In order to address this question, Rag -/-mice lacking the IL-7Rα chain (Rag -/-IL-7R
-/-) were reconstituted with OT-I T cells, received IL-7 therapy or PBS and were challenged with EG7 lymphoma cells. This approach allowed us to separate direct from indirect effects of rIL-7 on CD8 + T cell-mediated lymphoma rejection.
As compared to untreated controls, OT-I cells strongly delayed tumor growth in Rag -/-IL-7R
-/-recipients ( Fig 1B) similar to what we had observed in Rag -/-mice ( Fig 1A) . This demonstrates that host IL-7R-deficiency does not limit LIP-associated CD8 + T M differentiation (S1 Fig) and subsequent anti-tumor immunity ( Fig 1B) . In contrast to Rag -/-mice, rIL-7 treatment of OT-I- Fig 1C) . IL-7 signaling suppresses IL-7Rα chain (CD127) expression by naive T cells [32] . Accordingly, a strong and host-independent down-modulation of CD127 was observed 5 days after adoptive transfer and rIL-7 treatment (Fig 1D) . Importantly, OT-I T cells expressed less CD127 in PBS-treated Rag -/-IL-7R -/-than in Rag -/-mice arguing for elevated steady state IL-7 levels in the latter. Nevertheless, this did not affect the long-term abundance ( Fig 1C) or early rIL-7 responsiveness of OT-I T cells ( Fig 1D) .
In conclusion, host IL-7R signaling is dispensable for rIL-7-driven CD8 + T cell expansion ( Fig 1C) but not for subsequent tumor rejection. This highlights that high numbers of therapeutic CD8 + T cells do not necessarily correlate with therapeutic success.
Host IL-7R signaling is not required for rIL-7-induced T M differentiation but for granulocyte and DC expansion CD8 + T M express high levels of CD127 and the anti-apoptotic molecule B cell lymphoma protein-2 (Bcl-2) [33] , which can be up regulated by IL-7 [34] . In PBS-treated Rag -/-mice CD127 hi and Bcl-2 hi OT-I T M were less frequent than in Rag -/-IL-7R -/-mice (Fig 2A and 2B) . In response to rIL-7 treatment, however, resulting OT-I T M expressed elevated levels of CD127 and Bcl-2 in both hosts 21-25 days after transfer (Fig 2A and 2B) . Hence, despite early CD127 down-regulation (Fig 1D) , IL-7 therapy promoted the generation of CD127 hi Bcl-2 hi OT-I T M irrespective of the host. IL-7 therapy also promoted the generation of CD62L hi OT-I cells ( Fig   2C) expressing low levels of KLRG-1 (Fig 2D) . Furthermore, a high percentage of OT-I cells recovered from both hosts rapidly produced IFN-γ after short-term in vitro re-stimulation ( Fig 2E) . Hence, rIL-7 therapy favors the generation of functional CD8 + T M cells with a CD127 hi Bcl-2 hi CD62L hi KLRG-1 lo phenotype in a host-independent fashion. Interestingly, despite their high numbers ( Fig 1C) and favorable phenotype (Fig 2) , rIL-7-induced OT-I T M cells failed to reject tumors in Rag -/-IL-7R -/-mice ( Fig 1B) . This suggested a contribution of rIL-7-responsive host cells to EG7 elimination. After rIL-7 treatment, spleen cell numbers increased dramatically in Rag -/-mice ( Fig 3A) . In agreement with previous studies [24, 25] , CD11b + Gr-1 + granulocytes and CD11c + MHCII + DCs expanded most efficiently in response to rIL-7 (Fig 3B and 3C) . Among the latter, CD8 + lymphoid and CD8 -myeloid DCs responded similarly well (Fig 3D and 3E) . In Rag -/-
IL-7R
-/-mice rIL-7 therapy failed to induce the expansion of splenocytes, granulocytes and DCs ( Fig  3A-3E ) excluding IL-7R-independent side effects of our treatment regimen. In summary, host IL-7R signaling is crucial for rIL-7-induced, CD8 + T cell-mediated tumor rejection (Fig 1A and   1B ), is not essential for CD8 + T M differentiation (Fig 2) but promotes the expansion of granulocytes and DCs.
Host IL-7R signaling promotes CD8 + T cell expansion and modulates T M differentiation in response to peptide vaccination and IL-7 therapy IL-7 administration improves vaccination-induced T cell responses [13, 22] . To test whether this also requires host IL-7R signaling, Rag -/-mice, frequencies of CD62L hi OT-I cells were similar after vaccination (Fig 4C) . This was further increased by rIL-7 and was independent of host IL-7R expression (Fig 4C) . OT-I cells expressed similar levels of CD127 after vaccination of Rag -/-and Rag -/-IL-7R -/-mice. To our surprise, rIL-7 therapy further promoted CD127 expression by OT-I cells only in Rag -/-mice ( Fig 4D) . KLRG-1 hi OT-I cells were more frequent in vaccinated Rag -/-IL-7R -/-than in Rag -/-mice. In both hosts their abundance decreased in response to rIL-7, though to a lesser extent in Rag -/-IL-7R -/-mice (Fig 4E) . After vaccination, OT-I proliferation was lower in Rag -/-mice as shown by low numbers of Ki67 hi cells (Fig 4F) . Bcl-2 expression was similar in vaccinated Rag -/-and Rag -/-IL-7R -/-mice and was up regulated by rIL-7 only in the latter (Fig 4G) . In summary, the rIL-7-induced up-regulation of CD62L by OT-I cells was largely independent of IL-7R + host cells. In contrast, host cells promoted the expansion of OT-I cells (Fig 4B) and modulated their expression of CD127, KLRG-1 and Bcl-2 in response to rIL-7 therapy (Fig 4D, 4E and 4G). After vaccination, OT-I cells isolated from Rag -/-mice produced high levels of IFN-γ ( Fig   4H) . This response was less pronounced in Rag -/-IL-7R -/-mice but could be improved by rIL-7 treatment (Fig 4H) . Importantly, rIL-7 treatment could not further promote the generation of IFN-γ hi OT-I cells in Rag -/-mice (Fig 4H) . OT-I cells producing high levels of TNF-α were similarly frequent in Rag -/-and Rag -/-IL-7R -/-mice and further expanded in both hosts in response to rIL-7 treatment (Fig 4I) . The expression of PD-1, a marker for dysfunctional T cells, was comparable for OT-I cells recovered from mice of both strains. In agreement with a previous study [35] , rIL-7 administration reduced PD-1 expression on OT-I cells in Rag -/-mice (Fig 4J) .
Surprisingly, this was not the case in Rag -/-IL-7R -/-mice (Fig 4J) indicating that IL-7R + host 
IL-7R + non-hematopoietic cells are crucial for CD8 + T cell expansion in response to vaccination and rIL-7 therapy
Prolonged exposure to elevated levels of IL-7 down modulates il-7 gene activity in non-BMderived cells [4, 12] , which are the major source of IL-7 in vivo [20] . To determine whether non-hematopoietic cells respond to rIL-7 therapy, IL-7 reporter mice expressing luciferase under the control of the il-7 promoter [11] were treated with rIL-7. As a readout for il-7 gene activity, bioluminescence intensities (BLI) were determined before and after rIL-7 treatment. As shown in S2 Fig, rIL-7 administration reduced il-7 promoter activity significantly demonstrating that IL-7-producing non-BM-derived cells indeed respond to rIL-7 therapy.
In order to study the relative contribution of IL-7R signaling in hematopoietic versus nonhematopoietic host cells to rIL-7-induced CD8 + T cell responses, we generated bone marrow and -deficient DCs was comparable in Rag -/-BM recipients (R ! R vs RR ! R). On the contrary, DC expansion was strongly impaired in RR ! RR chimeras and only partially recovered in R ! RR chimeras (Fig 5B) . Hence, IL-7R signaling in non-BM cells is crucial for therapyassociated DC expansion. However, this appeared to be more important for CD8 + DCs than for CD8 -DCs (Fig 5C and 5D ). Fig 4B, OT-I responses were least efficient in chimeras lacking the IL-7R on BM-derived and non-BM-derived cells (Fig 5E; RR ! RR) . Importantly, IL-7R expression by BM-derived cells alone was insufficient to fully recover OT-I accumulation (Fig 5E; R ! RR) . IL-7 treatment is known to alter homing patterns of CD8 + T cells [36] . To exclude migration-related differences in splenic OT-I cell numbers, BM chimeras were reconstituted with renilla luciferase-transgenic (ChRluc tg ) CD8 + OT-I T cells [27] , vaccinated and treated with OT-I cells. However, their numbers were reduced in RR ! RR chimeras and lowest in R ! R and RR ! R chimeras (Fig 6A) . The frequencies of CD62L hi OT-I cells were identical in R ! R and RR ! RR chimeras suggesting their host IL-7R-independence (Fig 6B) . However, CD62L hi OT-I cells were less abundant in RR ! R and R ! RR (Fig 6B) . This indicates that IL-7R + BM-and non-BM-derived cells are part of a complex network exerting opposing functions on CD62L hi T M differentiation.
Similar to DCs, OT-I accumulation in the spleen was independent of IL-7R expression by BM derived cells if non-BM-derived cells expressed the IL-7R (Fig 5E; R ! R vs RR ! R). In accordance with
Highest levels of CD127 were found on OT-I cells from R ! R and RR ! R chimeras and lowest on those from RR ! RR chimeras (Fig 6C) demonstrating that IL-7R expression by non-BM cells is a prerequisite for maximum CD127 expression by CD8 + T cells. If only BMderived cells expressed the IL-7R (R ! RR) CD127 levels were significantly higher than in RR ! RR chimeras but still below those found on OT-I cells primed in RR ! R chimeras ( Fig  6C) . Thus, IL-7R + non-BM cells are major regulators of CD127 expression by OT-I cells.
The genes encoding Bcl-2 and CD8 are direct targets of IL-7 and other cytokines utilizing the IL-2Rγ c (CD132) for signal transduction [37] . CD127 lo OT-I cells from RR ! RR chimeras expressed highest levels of CD132, Bcl-2 and CD8 (Fig 6D-6F) suggesting that other CD132-dependent cytokines than IL-7 caused the differentiation of CD127 lo CD132 hi Bcl-2 hi CD8 hi T M cells in RR ! RR chimeras. In contrast, R ! R and RR ! R chimeras rather contained CD127 hi CD132 lo Bcl-2 lo CD8 lo OT-I cells (Fig 6C-6F) . However, if only BM-derived cells expressed the IL-7R (R ! RR) we observed an intermediate OT-I phenotype (Fig 6C-6G and 6F).
In response to rIL-7 treatment PD-1 was downregulated only on OT-I cells primed in Rag (Fig 4J) . In agreement with this, PD-1 expression was most pronounced in RR ! RR chimeras (Fig 6G) . PD-1 levels were significantly lower in both groups of chimeras expressing IL-7R on non-BM-derived cells and (R ! In summary, IL-7R + host cells promoted the expansion of CD8 + T M cells in response to rIL-7 therapy (Fig 4B-4J) . Surprisingly, regulatory host cells were mainly of non-BM origin (Figs 5E, 5F and 6).
The combination of rIL-7 therapy and peptide vaccination impairs T celldependent tumor rejection in Rag -/-mice CD8 + CD62L hi KLRG-1 lo IFN-γ hi PD-1 lo T M cells are well suited to provide long-term protection against chronic infections and tumors [7, 38, 39] . Peptide vaccination and rIL-7 therapy induced the generation of such T M cells in Rag -/-mice (Fig 4B-4J) , a process that was mainly controlled by IL-7R + non-hematopoietic cells (Figs 5E, 5F and 6). However, their therapeutic potential remained unclear. To test this, Rag -/-mice were reconstituted with CD8 + OT-I T cells and vaccinated with SIINFEKL one day later. Additionally, mice received rIL-7 or PBS according to the scheme described above. To ensure appropriate OT-I expansion and differentiation, mice were challenged with EG7 cells 21 days after adoptive T cell transfer. In untreated Rag -/-control mice, EG7 tumors grew rapidly (Fig 7A) . In contrast, 6/12 peptide-vaccinated Rag -/-mice remained tumor free (Fig 7A) . Surprisingly, however, only 2/12 Rag -/-mice rejected EG7
lymphomas after rIL-7 therapy (Fig 7A) . Importantly, this was not due to impaired DC expansion in rIL-7-treated Rag -/-mice ( Fig 7C) . Hence, the protective effect of peptide vaccination was blunted by rIL-7.
Correlating with their comparably low frequency ( Fig 4B) and KLRG-1 hi IFN-γ lo phenotype (Fig 4E and 4H ), SIINFEKL-induced T M cells rejected EG7 tumors only in 2/12 Rag -/-IL-7R
-/-mice ( Fig 7B) . After rIL-7 therapy only 1/12 Rag -/-IL-7R -/-mice remained tumor free (Fig 7B) .
In summary, the protective effect of peptide vaccination relied on host IL-7R signaling and was blunted by rIL-7 therapy.
Discussion
The major goal of our study was to clarify whether and how host IL-7R signaling contributes to rIL-7-driven anti-tumor CD8 + T cell responses. For this purpose, SIINFEKL-specific CD8 -/-and Rag -/-IL-7R -/-mice (n = 3). Statistical significance was calculated using the log-rank test. (C) The numbers of splenic DCs were determined in tumor-bearing mice 28-37 days after tumor challenge. Pooled data (±SEM) from 2 independent experiments with a total of 6-11 mice/group are shown. Statistical significance was calculated using the Mann-Whitney test. [24, 45] . Fibroblastic reticular cells (FRCs) and lymphoid endothelial cells (LECs) are major sources of IL-7 in secondary lymphoid organs [46] . Furthermore, other cells of non-BM origin such as intestinal epithelial cells (IECs) [47] , keratinocytes [48] , hepatocytes [49] and fibroblasts [50] were shown to produce IL-7 in vivo. The maintenance of CD8 + T cell homeostasis requires IL-7R signaling in CD8 + T cells which is triggered by IL-7 from non-BM derived cells [20] . However, only little is known about the consequences of IL-7R signaling in non-BM-derived cells and subsequent immune modulation [51] . As we have shown in S2 Fig, the application of rIL-7 leads to the systemic down-modulation of il-7 gene activity supporting previous reports demonstrating that il-7 gene activity is regulated in an IL-7-mediated negative feedback loop [4, 12] . Given that IL-7R signaling modulates gene expression profiles in multiple non-BM-derived cell types [4, 12, 26] , long-term rIL-7 therapy would not only affect immune cell but also nonimmune cell homeostasis. For instance, prolonged IL-7 overabundance promotes IEC expansion, survival and subsequent alterations in intestinal physiology [12] . Since many cell types of non-BM-derived origin can express the IL-7R [31] , the local down regulation of endogenous IL-7 production and alterations in tissue homeostasis might be as yet underestimated side effects of rIL-7 therapy. Whether i) non-BM-derived cells located in the tumor stroma and/or other tissues are the main targets of rIL-7, and ii) whether rIL-7 signaling in such cells promotes or suppresses rIL-7-assisted ATT remains to be shown. IL-7R + host cells appear to promote antigen-dependent CD8 + T cell function also in an IL-7-independent fashion. For example, successful peptide vaccination and subsequent tumor rejection, in the absence of rIL-7 treatment, strictly required host IL-7R expression (Fig 7A and  7B) . Importantly, however, peptide vaccination blocked the therapeutic effect of rIL-7 (Figs 1A and 7A) in Rag -/-mice although IL-7R-dependent DC expansion was normal (Fig 7C) . It has been reported that TCR signaling can interfere with the beneficial effects of IL-7 on T cells [52] . Hence, impaired tumor rejection in rIL-7-treated, peptide vaccinated Rag -/-mice might have been a result of altered T cell rather than host cell function. In summary, our data provide evidence for the complex interplay between IL-7R + host and were calculated in relation to those determined before treatment and relative BLI (rel. BLI) values were calculated. Shown are pooled data (± SEM) of 2 experiments with a total of 6 mice. Statistical analysis was performed using Wilcoxon matched-pairs signed rank test.
OT-I cells were transferred into
